Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 18NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × Practice Guidelines as Topic × Clear all
NCT05564390 2026-05-26

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡